← Back to Search

Beta-catenin/TBL1 Inhibitor

Tegavivint for Recurrent or Refractory Cancer

Phase 1 & 2

Recruiting

Led By Sarah B Whittle

Research Sponsored by Children's Oncology Group

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Creatinine clearance or radioisotope glomerular filtration rate (GFR) >= 70 mL/min/1.73 m^2 or a creatinine based on age/gender as follows (within 7 days prior to enrollment):

PART A: Patients must be >= 12 months and =< 21 years of age at the time of study enrollment

Must not have

Patients with a known metabolic bone disease (ex: hyperparathyroidism, Paget's disease, osteomalacia) are not eligible

Patients with known central nervous system (CNS) metastasis, except for craniopharyngeal tumors, will be excluded

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 60 months

Awards & highlights

Summary

This trial is testing a new drug to see if it can stop the growth of cancer cells.

Who is the study for?

This trial is for young people aged up to 21 or 30 years with recurrent or refractory solid tumors, including lymphomas and desmoid tumors. They must have measurable disease, be recovered from previous cancer treatments, meet specific blood count criteria, and not have severe bone diseases or uncontrolled infections. Pregnant individuals can't participate and those of reproductive potential must use effective birth control.Check my eligibility

What is being tested?

The trial is testing Tegavivint's highest safe dose and its effects on patients with stubborn solid tumors that resist treatment. Tegavivint aims to block tumor growth by disrupting signals within cells that encourage cell proliferation.See study design

What are the potential side effects?

Possible side effects include reactions related to the disruption of cellular signaling which could affect organ function but specifics are not detailed in the provided information.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

My kidney function is good based on recent tests.

Select...

I am between 12 and 21 years old.

Select...

I have a confirmed diagnosis of a solid tumor, non-Hodgkin lymphoma, or desmoid tumor that has come back or did not respond to treatment.

Select...

I am between 12 months and 30 years old.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:

Select...

I do not have a known metabolic bone disease.

Select...

I do not have brain metastasis, except for craniopharyngeal tumors.

Select...

I am not taking medication to prevent graft-versus-host disease after a bone marrow transplant.

Select...

I do not have any infections that are not under control.

Select...

My calcium levels are normal or can be corrected with oral supplements.

Select...

I do not have a condition that affects how my bones process minerals.

Select...

I do not have severe osteoporosis.

Select...

I have not taken denosumab in the last 6 months.

Select...

I do not have a primary brain tumor.

Select...

I am not taking any strong medication that affects enzyme CYP3A4.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 60 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 60 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 60 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Area under the drug concentration curve of tegavivint

Frequency of adverse events attributable to tegavivint

Frequency of dose limiting toxicities of tegavivint

Secondary outcome measures

Antitumor effects of tegavivint in patients with solid tumors

Trial Design

1Treatment groups

Experimental Treatment

Group I: Treatment (tegavivint)Experimental Treatment4 Interventions

Tegavivint will be administered IV over 4 hours on days 1, 8, and 15 of each cycle. Administer D5W flush after completion of each tegavivint infusion. Treatment repeats every 28 days for up to 26 cycles or 24 months in the absence of disease progression or unacceptable toxicity. Drug doses should be adjusted based on the weight (height and BSA will also be captured) measured within 7 days prior to the beginning of each cycle. The starting dose will be 5 mg/kg with dose levels for subsequent cohorts increasing to 6.5 mg/kg and 8 mg/kg if excessive toxicity does not occur. If the MTD has been exceeded at the first dose level, then the subsequent cohort of patients will be treated at a dose of 4 mg/kg. Patients undergo an x-ray at baseline, after cycle 1, and then every 3 cycles while on treatment and DEXA scan at baseline and every 6 cycles while on treatment, then at 12 months, 24 months, and annually up to 60 months following end of therapy.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Biospecimen Collection

2004

Completed Phase 2

~1720

Dual X-ray Absorptiometry

2015

N/A

~50

Tegavivint

2018

Completed Phase 1

~30

0 / 14Eligibility criteria met

Find a Location

Who is running the clinical trial?

Children's Oncology GroupLead Sponsor

456 Previous Clinical Trials

239,640 Total Patients Enrolled

National Cancer Institute (NCI)NIH

13,748 Previous Clinical Trials

40,959,254 Total Patients Enrolled

75 Trials studying Endometrial Cancer

73,304 Patients Enrolled for Endometrial Cancer

Sarah B WhittlePrincipal InvestigatorPediatric Early Phase Clinical Trial Network

Media Library

Tegavivint (Beta-catenin/TBL1 Inhibitor) Clinical Trial Eligibility Overview. Trial Name: NCT04851119 — Phase 1 & 2

Endometrial Cancer Research Study Groups: Treatment (tegavivint)

Endometrial Cancer Clinical Trial 2023: Tegavivint Highlights & Side Effects. Trial Name: NCT04851119 — Phase 1 & 2

Tegavivint (Beta-catenin/TBL1 Inhibitor) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04851119 — Phase 1 & 2

~87 spots leftby Jun 2028

Unbiased ResultsWe believe in providing patients with all the options.

Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.

Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.